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Background: Cognitive deterioration is a characteristic
symptom of Alzheimer's disease. This deterioration is
notably associated with structural changes and subsequent
cell death which occur, primarily, in acetylcholine-pro-
ducing neurons, progressively damaging cholinergic neu-
rotransmission. We have reported previously that excess
acetylcholinesterase (AChE) alters structural features of
neuromuscular junctions in transgenic Xenopus tadpoles.
However, the potential of cholinergic imbalance to induce
progressive decline of memory and learning in mammals
has not been explored.
Results: To approach the molecular mechanisms under-
lying the progressive memory deficiencies associated with
impaired cholinergic neurotransmission, we created trans-
genic mice that express human AChE in brain neurons.
With enzyme levels up to two-fold higher than in con-
trol mice, transgenic mice displayed an age-independent
resistance to the hypothermic effects of the AChE inhi-
bitor, paraoxon. In addition to this improved scavenging
capacity for anti-AChEs, however, these transgenic mice
also resisted muscarinic, nicotinic and serotonergic ago-
nists, indicating that secondary pharmacological changes
had occurred. The transgenic mice also developed pro-
gressive learning and memory impairments, although
their locomotor activities and open-field behaviour
remained similar to those of matched control mice. By
six months of age, transgenic mice lost their ability to
respond to training in a spatial learning water maze test,
whereas they performed normally in this test at the age of
four weeks. This animal model is therefore suitable for
investigating the transcriptional changes associated with
cognitive deterioration and for testing drugs that may
attenuate progressive damage.
Conclusion: We conclude that upsetting cholinergic
balance may by itself cause progressive memory decline in
mammals, suggesting that congenital and/or acquired
changes in this vulnerable balance may contribute to the
physiopathology of Alzheimer's disease.
Current Biology 1995, 5:1063-1071
Background
Progressive deterioration of memory and learning is a
characteristic manifestation of Alzheimer's disease [1].
The molecular mechanisms that underlie this phenome-
non are still obscure, as the vast majority (> 90 %) of
Alzheimer's disease cases originate sporadically - pre-
sumably as a result of multigenic contributions combined
with environmental causes [2]. There is therefore a need
to search for potential reasons to explain the progressive
cognitive decline in Alzheimer's disease.
At the neuropathological level, the neuritic plaques and
neurofibrillary tangles which are defining features of this
disease are particularly concentrated in brain regions
where cholinergic circuits operate [3]. Moreover, the
progression of disease symptoms is primarily associated
with structural changes in cholinergic synapses [4], the
loss of particular acetylcholine (ACh) receptor subtypes
[5], the death of ACh-producing neurons [6] and the
consequent damage to cholinergic neurotransmission [7].
These factors result in a relative excess of the ACh-
hydrolyzing enzyme, acetylcholinesterase (AChE). This
spatio-temporal correlation led to the cholinergic theory
of Alzheimer's disease [7] and promoted the development
of cholinergic therapies [8].
The first of the cholinergic drugs to be approved for
clinical use is tacrine (tetrahydroaminoacridine, THA,
Cognex®), an AChE inhibitor which temporarily attenu-
ates the worsening of certain clinical symptoms in patients
at the early stages of Alzheimer's disease [8]. The concept
behind the use of tacrine is to restore the cholinergic bal-
ance, at least for a while, by elevating ACh levels and aug-
menting the function of the remaining ACh receptors [9].
That tacrine administration has some therapeutic value
emphasizes the importance of balanced cholinergic neu-
rotransmission for satisfactory steady-state cognitive func-
tion. However, whether imbalanced cholinergic neuro-
transmission can, by itself, contribute to the progressive
decline in Alzheimer's disease has not been addressed.
To examine the consequences of synaptic cholinergic
imbalance in vivo, we have recently expressed human
AChE in transiently transgenic embryos of Xenopus laevis
frogs [10]. The recombinant human enzyme accumulated
in neuromuscular junctions and altered their structural fea-
tures [11]. Moreover, transgenic expression of the mouse
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muscle nicotinic ACh receptor induced similar structural
changes at Xenopus neuromuscular junctions, enlarging
their post-synaptic length and deepening their synaptic
cleft [11]. These alterations resembled those reported
for cholinergic brain synapses in patients at the early stages
of Alzheimer's disease [4], suggesting that these changes
could also be caused by imbalanced cholinergic neuro-
transmission. This, in turn, initiated our interest in creat-
ing-transgenic mice with congenital AChE overexpression
and examining cognitive function in such animals.
The construction of our transgenic mice was conceptu-
ally different from other recent models designed to
recreate the neuropathological features of Alzheimer's
disease. Transgenic mice expressing normal or mutant
forms of the 3-amyloid protein died prematurely [12] or
developed amyloid plaques rich in 13-amyloid peptides
[13]. This shed new light on the histopathological
changes that are characteristic of Alzheimer's disease,
particularly in carriers of 13-amyloid mutations, but not
on the relevant mental deficiencies. The elimination of
several key brain proteins by homologous recombination
(gene knockout) caused no histopathological changes,
but damaged spatial learning [14-16] or avoidance learn-
ing [17]. However, neither the -amyloid transgenic
mice nor any of these knockout mice were reported to
display the neurochemical changes particular to Alz-
heimer's disease, one of which is cholinergic imbalance.
Furthermore, none of the reported cognitive changes
appeared to involve progressive deterioration.
In contrast with the above studies, our efforts were
devoted to creating a subtle change in the normal bal-
ance of cholinergic neurotransmission within the mam-
malian brain, mimicking conditions that might exist in
patients with no hereditary tendency for Alzheimer's dis-
ease. We further limited this change to those cell types in
which it naturally takes place, and studied its neuro-
chemical, physiopathological and cognitive consequences
in an age-dependent manner. Our findings demonstrate
that AChE-overexpressing mice with inheritable cholin-
ergic imbalance undergo selective progressive decline in
their capacity for spatial learning and memory, and
indicate the usefulness of these mice for exploring the
detailed molecular mechanisms that underlie cognitive
deterioration in Alzheimer's disease.
Both promoters were shown previously to direct human
AChE accumulation in Xenopus neuromuscular junctions
[10,11], although the CMV promoter was approximately
ten-fold more efficient in its capacity to direct production
of the AChE protein in Xenopus [10].
We carried out parallel experiments with both constructs
to produce transgenic mice. In the first experiment, we
microinjected CMV-ACHE DNA into 70 mouse eggs,
but obtained only one viable founder mouse carrying the
CMV-ACHE transgene. However, the transgenic DNA
was not expressed in the progeny of that mouse. In the
second experiment, 40 microinjections of Hp-ACHE
DNA yielded three viable pedigrees with 2, 10 and 15
copies of the transgene, respectively. Of these, no enzyme
production was observed in the two pedigrees with higher
copy numbers of the transgene, but AChE was expressed
in the pedigree with two copies of the Hp-ACHE DNA.
The rate of success in obtaining viable AChE-transgenic
mice was considerably lower than we have observed pre-
viously with other microinjected DNAs [19,20], suggest-
ing that AChE overexpression was compatible with life
only at low levels. Seven generations of transgenic mice
with unmodified Hp-ACHE DNA were thereafter raised
from the successful pedigree, and all of them presented
grossly normal development, activity and behaviour.
Transgenic Hp-ACHE expression is limited to neurons of the
central nervous system
Reverse transcription and quantitative polymerase chain
reaction (PCR) amplification [20] revealed both human
and mouse ACHE mRNA transcripts in dissected brain
regions of the apparently homozygous transgenic mice
from the fifth and subsequent generations (Fig. 1). Host
ACHE mRNA levels and alternative splicing patterns
remained apparently unchanged [21]. Bone marrow and
adrenal glands expressed only mouse ACHE mRNAs,
Results
Low-level AChE overexpression is compatible with life
To produce transgenic mice overexpressing AChE, we
used two DNA constructs that included the ACHE cod-
ing sequence for the brain and muscle form of human
AChE [10]. In the first construct, this gene was preceded
by the potent ubiquitous promoter from cytomegalovirus
(CMV-ACHE construct) [18]. In the second construct,
this gene was preceded by a 596 base-pair fragment from
the authentic promoter of the human ACHE gene,
followed by its first intron (Hp-ACHE construct) [10].
Fig. 1. Identification of human ACHE mRNA. RNA was extracted
and amplified from transgenic (+) and control (-) mouse cortex
(C), brainstem and cerebellum (BC), basal forebrain (BF) and
bone marrow (BM). Species-specific PCR primers were designed
for the indicated positions within the open reading frame (dotted
underline) on the schemes above (see Materials and methods).
Resultant PCR products (276 and 786 bp, respectively) were
electrophoresed on agarose gels. Note that expression of human
ACHE mRNA was limited to the central nervous system.
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with apparently unmodified concentrations of the princi-
pal alternative products. Although the Hp-ACHE pro-
moter includes several MyoD-binding elements [10], the
transgene was not expressed in muscle.
To locate human Hp-ACHE mRNA transcripts in spe-
cific mouse brain cell types, we performed in situ hybri-
dization experiments. Labelling was observed in essentially
similar brain neurons to those observed in other mammals
[22,23]; these included cell bodies in the basal forebrain,
brainstem and cortex of the transgenic mice. Cholinocep-
tive hippocampal neurons were intensively labelled, espe-
cially in the CA1-CA2 region (Fig. 2). Thus, expression
of the Hp-ACHE transgene was apparently confined to
neurons of the host central nervous system (CNS) that
normally express the mouse ACHE gene.
Normally processed transgenic AChE accumulates in
cholinergic brain regions
AChE from the brains of control and transgenic mice
displayed similar sedimentation profiles in sucrose gradient
centrifugation, demonstrating unmodified assembly into
multimeric enzyme forms (Fig. 3). Up to 50 % of the
active enzyme in basal forebrain, but none in bone mar-
row, interacted with monoclonal antibodies specific to
human AChE (Fig. 3 and Table 1) [24]. Catalytic activity
measurements in tissue homogenates revealed a 100 %
increase over control levels in the detergent-extractable
amphiphilic AChE fraction from basal forebrain, and more
limited increments in cortex, brainstem, cerebellum and
spinal cord extracts (Table 1). There were no age-depen-
dent changes in this pattern and no differences in the
cell-type composition of the bone marrows of transgenic
and control mice. Gel electrophoresis followed by chemi-
cal staining for enzyme activity [24] revealed similar migra-
tion patterns for AChE fromthe brains of transgenic and
control mice, indicating comparable glycosylation patterns.
Fig. 3. Multimeric assembly of transgenic human AChE activity.
Acetylthiocholine hydrolysis levels were determined for basal
forebrain homogenates from transgenic and control mice after
sucrose gradient centrifugation prior to (clear areas), or following(blue area), adhesion to human-selective anti-AChE monoclonal
antibodies. Vertical arrows denote sedimentation of an internal
marker, bovine catalase (11.4 S).
Intensified cytochemical staining of AChE activity was
observed in brain sections from transgenic mice in all of
the areas that stain for AChE activity in normal mice
[25]. Staining was particularly intense in the neo-striatum
and pallidum (Fig. 4a,b) as well as in the hippocampus
(Fig. 4c,d); the latter two areas are associated with learn-
ing and memory [26,27]. Moreover, depositions of the
electron-dense product of AChE-cytochemical staining
were more conspicuous within synapse-forming den-
drites in the anterior hypothalamus from transgenic mice
than in control brain sections (Fig. 4e,f and Table 2).
However, synapses interacting with these stained den-
drites were of similar lengths in transgenic mice and in
controls (Table 2), demonstrating that, unlike the situa-
tion in Xenopus laevis neuromuscular junctions [11,24],
AChE overexpression in the mouse brain did not modify
the post-synaptic length of (at least part of) the cholin-
ergic synapses. In addition, there was no indication of
Fig. 2. Expression of transgenic Hp-ACHE mRNA in mouse brain
neurons. Whole-mount in situ hybridizations were performed on
fixed brain sections from (a) transgenic and (b) control mice.
CA1 hippocampal neurons (bracketed) were intensely labelled in
the transgenic, but not the control, section.
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neurofibrillary tangles or amyloid plaques in the analyzed
brain sections from mice up to six months of age.
Transgenic AChE selectively alters hypothermic drug
responses
To investigate the physiological effects of overexpressing
transgenic AChE, and because cholinergic synapses in the
anterior hypothalamus (where we noted AChE overex-
pression) are known to be involved in thermoregulation
[28], we examined the responses of transgenic mice to
drugs causing hypothermia. The potent AChE inhibitor
diethyl p-nitrophenyl phosphate (paraoxon) is the toxic
metabolite of the agricultural insecticide parathion; both
young (4-5 weeks) and adult (5-7 months) transgenic
mice were considerably more resistant to paraoxon-
induced hypothermia than non-transgenic controls (Fig.
5a,b). The transgenic mice were almost totally resistant to
a low paraoxon dose (0.25 mg kgl, Fig. 5a). With higher
doses, they displayed limited reduction in body tempera-
ture and shorter duration of response than controls (Fig.
5b). Most importantly, transgenic mice exposed to a
1 mg kg -1 dose of paraoxon retained apparently normal
physical activity, whereas control mice experienced myo-
clonia and muscle stiffening, symptoms characteristic of
cholinergic over-stimulation.
Fig. 4. Neuronal localization of AChE. (a-d) Cells that express
AChE. Wholemount cytochemical staining of AChE activity was
performed on fixed sections of (a,c) control and (b,d) transgenic
brains. Neuronal cell bodies in (a,b) caudate-putamen (CP),
globus pallidus (GP) and (c,d) hippocampal regions CA2 and
CA3 were stained more intensely in transgenic than in control
brain. Scale bars: (a,b)= 1mm; (c,d) 100 pLm. (e,f) Dendritic
accumulation of AChE. Cytochemical staining of AChE activity
and electron microscopy were performed on fixed brain sections
including axo-dendritic terminals from the anterior hypothala-
mus. Excess electron-dense reaction products appeared as dark
grains within dendrites (centre of field) in (f) transgenic brain as
compared with low-density labelling in (e) control brain. Scale
bar = 0.5 pIm.
In addition to their improved capacity for scavenging
paraoxon, the transgenic mice also displayed resistance to
the hypothermic effects of the muscarinic agonist oxo-
tremorine (Fig. 5c), to the less potent effect of nicotine
(Fig. 5d), and to the serotonergic agonist 8-hydroxy-2-
(di-n-propylamino) tetralin (8-OH-DPAT) (Fig. 5e), but
not to the a 2-adrenergic agonist clonidine (Fig. 5f).
However, the thermal response to cold exposure remained
unchanged in both transgenic and cntrol mice: after 60
minutes of exposure to 5 C, the body temperature of all
mice had decreased to 35.5 C, indicating that no changes
had occurred in their peripherally induced control over
body temperature (data not shown).
Transgenic AChE induces an age-dependent decline in
spatial learning capacity
To examine their cognitive functioning, transgenic and
control mice were subjected to several behavioural tests.
At the ages of one, two-three and five-seven months,
transgenic mice retained normal locomotor and explor-
ative behaviour, covering the same space and distance in
an open field as sex-matched groups of non-transgenic
control mice. The open field anxiety of the mice also
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remained similar, as evaluated in the frequency of defeca-
tion incidents and grooming behaviour (Table 3).
Conspicuous behavioural differences between the trans-
genic and control mice were observed, however, in two
versions of the Morris water maze [29]. In the hidden
platform version of this test, mice are expected to use
long-distance cues to orient themselves, to find a plat-
form submerged under opaque water and to escape a
swimming task [29]. The performance of the transgenic
mice was apparently normal in this test at the young age
of four weeks - they needed a similar number of train-
ing sessions as compared to control mice in order to
reach the platform within a significantly shorter time
(defined as the escape latency) than untrained mice
(Fig. 6a and Table 3). At the age of two or three months,
transgenic mice needed eight more training sessions than
control mice to improve their performance; the variation
between animals also increased, and their shortest escape
latency was significantly longer than that of control mice
of the same age (Fig. 6b and Table 3). At the age of six
months, naive transgenic mice, but not control mice,
became totally incapable of improving their performance
60 90 120 0
Time (min)
30 60 90 120 150 180
o Control
* Transgenic
Fig. 5. Transgenic mice display reduced hypothermic responses
to cholinergic and serotonergic, but not adrenergic, agonists.
Core body temperature was measured in control and transgenic
mice, five-seven months old, at the noted times, after intraperi-
toneal injections of the marked doses of (a,b) paraoxon, (c)
oxotremorine, (d) nicotine, (e) tetralin (8-OH-DPAT) or (f) cloni-
dine. Presented are average data for (a,f) five or (c-e) four male
and female mice, or (b) one representative pair out of three tested.
Note different time and temperature scales. Temperatures of
transgenic mice at all time points after 10 min from injection
were statistically different from those of controls for oxotremorine,
nicotine and 8-OH-DPAT (Student's t test, p < 0.05).
Fig. 6. Progressive impairment in spatial learning and memory of
Hp-ACHE transgenic mice. Mice were tested in a water maze
with a hidden platform in a fixed location. Averages of daily
mean escape latencies are presented for (a) four-weeks-old
transgenic (n = 10) and control (n = 5) mice, (b) two-months-old
transgenic (n = 10) and control (n = 10) mice and (c) five-seven-
months-old transgenic (n = 9) and control (n = 11) mice. Stars
mark statistically significant reductions of latencies, as compared
with the first day values in each section (one-way ANOVA,
followed by Neuman Keuls test, p < 0.02).
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in this test through training, such that their escape
latency remained the same as that of untrained mice
(Fig. 6c and Table 3).
This pattern of deterioration was not caused by locomo-
tor deficiencies, as was clear when the two groups of mice
were compared in the open field test (see above). It could,
therefore, reflect changes in memory. Alternatively, or in
addition, changes in the acquisition of learning could be
involved, which might be affected by motivational fac-
tors. It should be noted that the progressive behavioural
decline of these transgenic mice was more pronounced
than that observed in mice with targetted mutations
in the glutamate receptor 1 [14], the kinase Fyn [15] or
calcium calmoduline kinase II [16], suggesting a more
substantial perturbation than in any of these cases.
A different, age-independent defect was observed in the
visible platform version of the Morris water maze, in
which mice are trained to escape the swimming task by
using short-distance cues to climb on a visible platform
decorated by a flag and a paper cone [29]. Interestingly,
the transgenic mice could not improve their perfor-
mance in this test through training, regardless of their
age (Table 3), perhaps due to early-onset difficulties in
short-distance vision or because of abnormal avoidance
behaviour. In either case, the early occurrence of this
defect at the age of four weeks, when the hidden plat-
form test was still correctly performed by the transgenic
mice, demonstrates that the defects in the visual and the
hidden platform test were unrelated.
Discussion
Using the authentic promoter from the human ACHE
gene in conjunction with the AChE-coding sequence,
we created transgenic mice expressing human AChE in
CNS neurons. The levels of overexpression were appar-
ently sufficiently low to be compatible with life. The
transgenic enzyme was processed normally and was detec-
ted preferentially in brain areas that normally express
AChE, where it affected the responses of the transgenic
animals to drugs causing hypothermia. Most impor-
tantly, there was a rapid decline in the spatial learning
capacities of these transgenic animals, initiated in early
adulthood and becoming progressively more severe, sup-
porting the notion that subtle cholinergic imbalance can
cause progressive learning deficiencies in mammals.
Our failure to obtain viable mice with high levels of
AChE overexpression may imply that both the Hp-
ACHE promoter, with its limited efficacy, and the low
copy numbers of the transgene were important in allow-
ing survival of the ACHE-transgenic mice. The expres-
sion pattern of the transgene excluded peripheral organs
where the ACHE gene is normally expressed [30-32]; in
particular, there was no expression in muscle, although
MyoD-binding elements are included in the Hp-ACHE
promoter. The restriction of expression to CNS neurons
may occur because the promoter is incomplete, missing
necessary enhancer elements. Alternatively, silencing ele-
ments in the promoter, similar to those reported in
upstream sequences of the choline acetyltransferase gene
[33], could prevent expression of this transgene in its
normal target tissues. Finally, the insertion site within the
host genome may affect expression. Additional studies
will be required to distinguish between these possibilities.
The limited neuronal expression and low copy number
of the transgene ensured that it could only cause a subtle
cholinergic imbalance. The transgenic protein was pro-
cessed and assembled normally, presumably due to the
extremely high homology (95 %) between the human
and the mouse enzymes [30-32]. It therefore accumu-
lated in all of the relevant sites, with its highest excess
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levels being found in the basal forebrain - the region
most vulnerable to neuronal loss in Alzheimer's disease
[1]. Interestingly, cholinergic synapses within the brains
of the transgenic mice retained their normal length,
unlike neuromuscular junctions from AChE-overexpress-
ing Xenopus tadpoles. However, the Xenopus synapses also
accumulated up to ten-fold more AChE [11,24]; in
contrast, enzyme excess was limited to two-fold in the
mouse synapses analyzed, perhaps reflecting an upper
limit compatible with survival in mammals. The question
of whether cholinergic imbalance can cause progressive
structural changes to other particular types of cholinergic
synapses in the mammalian brain must await further
examination.
The resistance of transgenic mice to the induction of
hypothermia by different agents demonstrated that the
functioning of cholinergic synapses was modified by the
overexpression of human AChE. Resistance to para-
oxon was to be expected, as the amount of its target
protein, AChE, was significantly increased in the brains
of these mice. However, the resistance to muscarinic,
nicotinic and serotonergic agonists reflected secondary
changes affecting both cholinergic and serotonergic
synapses, or perhaps only cholinergic ones - a recent
report demonstrates that 8-OH-DPAT affects nicotinic
receptors directly [34]. These changes were caused, either
directly or indirectly, by the transgenic enzyme. How-
ever, no general alterations occurred in the network of
neurons controlling thermoregulation, as the transgenic
mice retained normal responses to noradrenergic agents
and to cold exposure. This suggests a loss of specific
synapses and/or receptor desensitization as possible cau-
ses, and indicates the use of cholinergic and serotonergic
agonists for the early diagnosis of imbalanced cholinergic
neurotransmission in human patients.
From their young adulthood onward, and also at a time
when their spatial learning performance with a hidden
platform was indistinguishable from that of controls, our
transgenic mice failed to respond to short-distance visi-
ble cues. This could reflect a particular avoidance behav-
iour or could be due to the inability of these mice to
focus their eyesight on a nearby target. The latter pos-
sibility is reminiscent of the differential response of
Alzheimer's disease patients to tropicamide [35]. It is
possible that autonomic control over pupil constriction
and eyesight-focusing muscles requires precisely balanced
cholinergic neurotransmission. It will be intriguing to
examine whether Alzheimer's disease patients have more
difficulties in focusing on nearby targets than unaffected,
similarly-aged patients.
Of particular interest are the gradual spatial memory
deficits displayed by the AChE-overexpressing transgenic
mice in the hidden platform water maze, as opposed to
their normal open field behaviour. The onset of these
impairments in early adulthood suggests that the cholin-
ergic balance essential for spatial memory can be sus-
tained in younger transgenic mice, perhaps by a feedback
mechanism that adjusts other key elements in cholinergic
synapses. This intricate process resembles the increase in
xo-bungarotoxin binding levels in Xenopus embryos that
overexpress AChE, and the reciprocal AChE accumula-
tion in neuromuscular junctions of tadpoles expressing
the mouse nicotinic ACh receptor [11]. Further to these
observations, we now learn that, in mammals, this adjust-
ment of the cholinergic balance can only be maintained
for a limited time.
Several mechanisms of various levels have been impli-
cated in the control of CNS cholinergic balance. Various
ACh receptor genes have been shown to share common
promoter elements [36,37], thus ensuring co-regulation
by trans-acting factors. Furthermore, a single cis-acting
promoter controls the production of both the vesicular
ACh transporter and choline acetyltransferase [38,39]. A
gradual failure to maintain either or both of these mech-
anisms, or others, may be involved in the progressive
changes observed in our mice. The appearance of mem-
ory perturbation in the early stages of Alzheimer's dis-
ease may similarly signal the onset of failure to sustain
cholinergic balance at the precise levels required for
memory. The increase in brain AChE activity under
stress [40] and the heterogeneous genomic origin of
Alzheimer's disease in the vast majority of patients [2]
may indicate that failure to maintain cholinergic balance
can be due to variable causes.
The possibility exists that the overexpression of AChE
may have effects that relate to the potential non-catalytic
function(s) of this intriguing protein. Although the phe-
notypic differences observed in the transgenic mice are
most probably correlated with acetylcholine hydrolysis,
further experiments should be performed to explore any
correlation with the potential functions of AChE in cell-
to-cell interactions [41,42]. Indeed, evidence accumu-
lated from patients suggests that AChE per se is closely
linked to Alzheimer's disease: in patients, the brain ratio
between AChE monomers and tetramers is significantly
modified [43]; in the adrenal gland, selective AChE
depletion has been observed [44]; and in the cerebro-
spinal fluid, a catalytically active AChE form with an
anomalous isoelectric point has been detected [45]. These
observations indicate that a functional excess of AChE
might, independent of the catalytic site, be subsequently
exerting new and possibly dangerous roles.
In either case, the gradual impairment of learning and
memory due to AChE overexpression is consistent with
the temporary partial improvement seen when anti-
AChE drugs are administered to Alzheimer's disease
patients [8,9]. Moreover, preliminary differential PCR
displays [46,47] of mRNA from dissected brain regions
of our transgenic mice have revealed age-dependent
transcriptional changes, which await characterization.
This approach may unravel the target genes being affec-
ted by the transgene. Testing the effects of drug treat-
ments on the progressive transcriptional changes that
occur in the brain of these mice might thereafter lead to
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the development of novel strategies for prophylactic
treatment of neurodegenerative disorders associated with
cholinergic imbalance.
Finally, although AChE-overexpressing mice provide a
model for behavioural, physiological and molecular
aspects of cholinergic imbalance in mammals, they also
demonstrate a dissociation between this imbalance and
the P-amyloid deposits that occur in Alzheimer's disease.
The possibility remains that cholinergic neurons are par-
ticularly sensitive to the neurotoxicity attributed to the
P-amyloid peptides [12,13], in which case 3-amyloid
transgenic mice should develop cholinergic deficiencies
with time. Alternatively, or in addition, cholinergic
imbalance Ipay lead to abnormal -amyloid expression,
in which case the AChE transgenic mice should develop
13-amyloid deposits with time. A third possibility is that
the linkage between the pathophysiological and the
cognitive manifestations in Alzheimer's disease is unique
to Homo sapiens.
Conclusions
Expression of human AChE in CNS neurons of trans-
genic mice creates impairments in spatial learning and
memory which appear shortly after early adulthood and
become progressively more severe. From early adult-
hood, these mice also show a marked, yet stable, decrease
in performance in a visible water maze test. The open-
field behaviour of the transgenic animals remains nor-
mal, although their responses to hypothermia-inducing
drugs are decreased. These findings suggest that subtle
alterations in cholinergic balance may cause physiologi-
cally observable changes and contribute to memory
deterioration in at least some patients with sporadic
Alzheimer's disease.
Materials and methods
Production of transgenic mice
DNA constructs were injected into fertilized eggs of FZB/N
mice as described [19,20]. PCR amplification and Southern
blot hybridization of tail DNA samples verified integration of
variable copy numbers of the transgene into the genomes of
founder mice and their progeny.
RNA extraction and PCR amplification
These were performed as detailed [20], except that the anneal-
ing temperature was 69 C. Species-specific PCR primers were
designed for human ACHE mRNA at nucleotides 1522(+) and
1797(-) in exons 3 and 4 [24], and for mouse at nucleotides
375(+) and 1160(-) in exons 2 and 3 [21]. Resultant PCR
products (276 and 786 bp, respectively) were electrophoresed
on agarose gels.
In situ hybridization
Wholemount in situ hybridizations were performed at 65 C on
50 pIm-thick, 4 % paraformaldehyde/1 % glutaraldehyde-fixed
sections of transgenic and control brains with digoxigenin-
labelled complementary human ACHE cRNA. Detection was
with alkaline-phosphatase-conjugated anti-digoxigenin antibody
(Boehringer/Mannheim).
AChE activity measurements
Acetylthiocholine hydrolysis levels were determined, following
sucrose gradient centrifugation of tissue homogenates, prior to
or following adhesion to human-selective anti-AChE mono-
clonal antibodies, essentially as detailed [24,32].
AChE cytochemical staining
Whole-mount cytochemical staining of AChE activity was
performed on 50 lim-thick, paraformaldehyde-glutaraldehyde-
fixed sections of brains as detailed [24], except that incubation
was for 2 h. Electron microscopy was thereafter performed on
80 nm sections of paraformaldehyde-glutaraldehyde-fixed brain
[24]. Control experiments with no acetylthiocholine verified
that these electron-dense deposits were indeed reaction
products of in situ AChE catalysis.
Hypothermic response measurements
Core body temperature was measured rectally in mice, using a
thermocoupled element of 1 mm diameter and 10 mm length,
at the noted times after intraperitoneal injections of paraoxon,
oxotremorine, nicotine, tetralin (8-OH-DPAT) or clonidine.
Morris water maze tests
Mice were tested in a 60 x 60 x 15 cm water maze filled with
1.5 mg 1-1 powdered milk, with a submerged hidden platform
in a fixed location 1 cm below water level. Four trials of up to
2 min were performed per day for four days, each initiated ran-
domly in a different comer of the maze. For the visual platform
test, the water level was lowered by 2 cm, and a 10 cm high
striped flag and a 7 cm high black cone were positioned on top
of the now visible platform. Mean escape latencies per day
(four sessions) were calculated for transgenic and sex- and age-
matched controls, and statistically significant reductions of
latencies were searched for as compared with the first day val-
ues in each section (one-way ANOVA, followed by Neuman
Keuls test).
Open field test
Mice were placed in one corner of a 60 x 60 cm Plexiglass box
with 30 cm high walls and the floor divided into 144 squares of
5 x 5 cm each. Using these squares, the motion path of the
animals was manually traced for 5 min, which enabled mea-
surements of walking distance and explored area. Grooming
behaviour and incidence of defecations were also noted.
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Erratum
Involvement of MAP kinase in insulin signalling
revealed by non-invasive imaging of luciferase
gene expression in single living cells
Guy A. Rutter, Michael R.H. White and Jeremy M. Tavare
Current Biology 1995, 5:890-899
In this paper, which appeared in the 1 August 1995 issue
of Current Biology, part of Figure lb was inadvertently
omitted. The correct version of the figure is reprinted on
the right.
Fig. 1. Regulation of AP-1 activity by insulin in single living cells.
(a) CHO.T cells were microinjected with plasmid pCol.Luc
(0.4 mg ml-') and then incubated in the absence or presence of
100 nM insulin as shown. The image represents a 15 min data
collection period. (b) Cells were microinjected with pCol.Luc
and simultaneously incubated in serum-free Ham's F12 medium
supplemented with 1 mM luciferin and 100 nM insulin. Each
image represents a 30 min data collection period. Note the divi-
sion of the arrowed cell and the motility of its daughter cell. (c)
The number of photons detected from each of the cells shown in
(b) was quantified using the area analysis program (Argus-50 soft-
ware). The plot shows the induction of luciferase as a function of
time in 11 individual cells.
© Current Biology 1995, Vol 5 No 91072
Corrigenda
Targeting the mouse genome: a compendium of knockouts
E.P. Brandon, R.L. Idzerda and G.S. McKnight
Current Biology 1995, 5:625-634; 758-765; 873-881
The following omissions and errors in the entries up to
the end of 1994 have come to light so far.
Omissions
CD23
Only one paper was referenced when, in fact, there have
been three independent knockouts of CD23. The miss-
ing "initial reports" are:
Stief A, Texido G, Sansig GC, Eibel H, Legros G, Vanderputten H: Mice
deficient in CD23 reveal its modulatory role in IgE production but no
role in T and B cell development. J Immunol 1994, 152:3378-3390.
Yu P, Koscovilbois M, Richards M, Kohler G, Lamers MC: Negative feed-
back regulation of IgE synthesis by murine CD23. Nature 1994,
369:753-756.
To allow for all three papers, the "phenotype" for CD23
should be changed to: Defects in IgE regulation and
IgE-mediated signalling.
CD28
A "follow up" paper that was missed is:
Green JM, Noel PJ, Sperling Al, Walunas TL, Gray GS, Bluestone JA,
Thompson CB: Absence of B7-dependent responses in CD28-deficient
mice. Immunity 1994, 1:501-508.
CD40
This did not appear in the compendium. The "initial
report" is:
Kawabe T, Naka T, Yoshida' K, Tanaka T, Fujiwara H, Suematsu S
et al.: The immune responses in CD40-deficient mice: Impaired
imunoglobulin class switching and germinal center formation. Immunity
1994,1:167-178.
The "phenotype" is: Defects in thymus-dependent hu-
moral immunity.
CD40L
Only one paper was referenced when, in fact, there have
been two independent knockouts of CD40L. The miss-
ing "initial report" is:
Xu JC, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore
J, Noelle RJ, Flavell RA: Mice deficient for the CD40 ligand. Immunity
1994, 1:423-431.
The "phenotype" of the pair of papers should be:
Defects in thymus-dependent humoral immunity".
Ik (Ikaros gene products)
This did not appear in the compendium. The "initial
report" is:
Georgopoulos K, Bigby M, Wang J-H, Molnar A, Wu P, Winandy S,
Sharpe A: The Ikaros gene is required for the development of all
lymphoid lineages. Cell 1994, 79:143-156.
The "phenotype" is: Neonatal lethality; reduced size;
lymphocytes and lymphoid progenitors absent.
Interferon a/1 receptor
This did not appear in the compendium. The "initial
report" is:
Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM
et al.: Functional role of type I and II interferons in anti-viral defense.
Science 1994, 264:1918-1921.
The "phenotype" is: Anti-viral defence impaired. (see
Corrections).
Invariant chain
A "follow up" paper that was missed is:
Elliot EA, Drake JR, Amigorena S, Elsemore J, Webster P, Mellman I,
Flavell RA: The invariant chain is required for intracellular transport and
function of major histocompatibility complex class II molecules. I Exp
Med 1994, 179:681-694.
L-Selectin
This did not appear in the compendium. The "initial
report" is:
Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten GC,
Capon DJ, Tedder TF: Lymphocyte homing and leukocyte rolling and
migration are impaired in L-selectin-deficient mice. Immunity 1994,
1:247-260.
The "phenotype" is: Defects in lymphocyte homing and
leukocyte rolling and migration.
Corrections
Interferon y receptor
The "follow up" paper [253] primarily reports the initial
report of a knock-out of the interferon o/3 receptor (see
Omissions).
Oxidase cytochrome b
This entry should have been listed as: Cytochrome b,
phagocyte-specific oxidase
Int-2 (FGF3)
This entry might have been better listed as: Fibroblast
growth factor 3 (FGF3) (int-2)
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